TRAW

SEC source: 0001203603-26-000003 · form4-07152026_010731.xml · derivative · entry 1

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001681955-26-000002 · form4-07152026_120715.xml · derivative · entry 1

Dukes Iain D. · CIK 0001681955 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 274,000

Underlying: Common Stock · 274,000 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002018274-26-000003 · form4-07152026_120748.xml · derivative · entry 1

Redfield Robert · CIK 0002018274 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,000

Underlying: Common Stock · 84,000 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002125562-26-000005 · form4-07152026_120746.xml · derivative · entry 1

Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001813552-26-000004 · form4-07152026_120707.xml · derivative · entry 1

Shoemaker Mary Teresa · CIK 0001813552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001958857-26-000003 · form4-07152026_120706.xml · derivative · entry 1

Clarke Trafford · CIK 0001958857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001586657-26-000003 · form4-07152026_120728.xml · derivative · entry 1

Leaman John Harold · CIK 0001586657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001237419-26-000003 · form4-07162026_010736.xml · derivative · entry 1

CAUTREELS WERNER · CIK 0001237419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,150

Underlying: Common Stock · 14,150 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002017800-26-000003 · form4-07152026_080727.xml · derivative · entry 1

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,000

Underlying: Common Stock · 93,000 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002018150-26-000003 · form4-07162026_040743.xml · derivative · entry 1

Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,000

Underlying: Common Stock · 97,000 shares

Expires 2036-07-09

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0000947871-26-000481 · ownership.xml · derivative · entry 4

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,793,187

Underlying: Common Stock · 1,793,187 shares

Expires not disclosed

F1 · price: On April 15, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain investors (the "Investors"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the "Closing Date") Series A warrants, Series B warrants, and Series C warrants (collectively, the "Warrants") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673.

F2 · derivative.exercise_date: The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.

F2 · derivative.expiration_date: The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000481 · ownership.xml · derivative · entry 3

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 597,729

Underlying: Common Stock · 597,729 shares

Expires not disclosed

F1 · price: On April 15, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain investors (the "Investors"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the "Closing Date") Series A warrants, Series B warrants, and Series C warrants (collectively, the "Warrants") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673.

F2 · derivative.exercise_date: The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.

F2 · derivative.expiration_date: The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000481 · ownership.xml · derivative · entry 2

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 597,729

Underlying: Common Stock · 597,729 shares

Expires not disclosed

F1 · price: On April 15, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain investors (the "Investors"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the "Closing Date") Series A warrants, Series B warrants, and Series C warrants (collectively, the "Warrants") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673.

F2 · derivative.exercise_date: The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.

F2 · derivative.expiration_date: The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0000947871-26-000481 · ownership.xml · nonDerivative · entry 1

ORBIMED ADVISORS LLC · CIK 0001055951 · 10% owner

OrbiMed Capital GP VIII LLC · CIK 0001845804 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 1,203,250

F3 · ownership.nature: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.

F4 · ownership.nature: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

SEC source: 0001237419-26-000002 · form4-03102026_110356.xml · derivative · entry 1

CAUTREELS WERNER · CIK 0001237419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,258

Underlying: Common Stock · 31,258 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001958857-26-000002 · form4-03102026_110349.xml · derivative · entry 1

Clarke Trafford · CIK 0001958857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,435

Underlying: Common Stock · 33,435 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001586657-26-000002 · form4-03102026_110339.xml · derivative · entry 1

Leaman John Harold · CIK 0001586657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,435

Underlying: Common Stock · 33,435 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001681955-26-000001 · form4-03102026_110302.xml · derivative · entry 1

Dukes Iain D. · CIK 0001681955 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 231,336

Underlying: Common Stock · 231,336 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002018150-26-000002 · form4-03102026_110321.xml · derivative · entry 1

Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,367

Underlying: Common Stock · 118,367 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002017800-26-000001 · form4-03102026_110301.xml · derivative · entry 1

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,899

Underlying: Common Stock · 96,899 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001203603-26-000001 · form4-03102026_110316.xml · derivative · entry 1

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,435

Underlying: Common Stock · 33,435 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002018274-26-000002 · form4-03102026_110357.xml · derivative · entry 1

Redfield Robert · CIK 0002018274 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,854

Underlying: Common Stock · 108,854 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001813552-26-000002 · form4-03102026_110357.xml · derivative · entry 1

Shoemaker Mary Teresa · CIK 0001813552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,435

Underlying: Common Stock · 33,435 shares

Expires 2036-03-08

F1 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002125562-26-000004 · form4-04082026_060446.xml · derivative · entry 4

Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,544

Underlying: Common Stock · 104,544 shares

Expires 2036-03-08

F4 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0001586657-25-000008 · form4-12162025_111250.xml · derivative · entry 2

Leaman John Harold · CIK 0001586657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,234

Underlying: Common Stock · 16,234 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001586657-25-000008 · form4-12162025_111250.xml · nonDerivative · entry 1

Leaman John Harold · CIK 0001586657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,058

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0001958857-25-000007 · form4-12162025_111241.xml · derivative · entry 2

Clarke Trafford · CIK 0001958857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,629

Underlying: Common Stock · 24,629 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001958857-25-000007 · form4-12162025_111241.xml · nonDerivative · entry 1

Clarke Trafford · CIK 0001958857 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,157

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0001237419-25-000004 · form4-12162025_111247.xml · derivative · entry 2

CAUTREELS WERNER · CIK 0001237419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,496

Underlying: Common Stock · 19,496 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001237419-25-000004 · form4-12162025_111247.xml · nonDerivative · entry 1

CAUTREELS WERNER · CIK 0001237419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,222

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0001813552-25-000005 · form4-12162025_111254.xml · derivative · entry 2

Shoemaker Mary Teresa · CIK 0001813552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,629

Underlying: Common Stock · 24,629 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001813552-25-000005 · form4-12162025_111254.xml · nonDerivative · entry 1

Shoemaker Mary Teresa · CIK 0001813552 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,292

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0001203603-25-000006 · form4-12162025_111205.xml · derivative · entry 2

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,629

Underlying: Common Stock · 24,629 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001203603-25-000006 · form4-12162025_111205.xml · nonDerivative · entry 1

STOVER JACK E · CIK 0001203603 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,165

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0001681955-25-000004 · form4-12162025_111223.xml · derivative · entry 2

Dukes Iain D. · CIK 0001681955 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,771

Underlying: Common Stock · 147,771 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001681955-25-000004 · form4-12162025_111223.xml · nonDerivative · entry 1

Dukes Iain D. · CIK 0001681955 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,130

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0002018150-25-000004 · form4-12162025_111219.xml · derivative · entry 2

Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,886

Underlying: Common Stock · 73,886 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0002018150-25-000004 · form4-12162025_111219.xml · nonDerivative · entry 1

Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,971

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0002018274-25-000004 · form4-12162025_111226.xml · derivative · entry 2

Redfield Robert · CIK 0002018274 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,676

Underlying: Common Stock · 65,676 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0002018274-25-000004 · form4-12162025_111226.xml · nonDerivative · entry 1

Redfield Robert · CIK 0002018274 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,919

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0002017800-25-000004 · form4-12162025_111258.xml · derivative · entry 2

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,676

Underlying: Common Stock · 65,676 shares

Expires 2035-12-12

F2 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0002017800-25-000004 · form4-12162025_111258.xml · nonDerivative · entry 1

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,606

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0002125562-26-000004 · form4-04082026_060446.xml · derivative · entry 3

Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,571

Underlying: Common Stock · 61,571 shares

Expires 2035-12-12

F3 · derivative.exercise_date: Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.

SEC source: 0002125562-26-000004 · form4-04082026_060446.xml · nonDerivative · entry 1

Parker Charles Nolan · CIK 0002125562 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,393

F1 · shares: Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.

SEC source: 0001586657-25-000007 · form4-11252025_111110.xml · derivative · entry 1

Leaman John Harold · CIK 0001586657 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,770

Underlying: Common Stock · 12,770 shares

Expires 2035-11-21

F1 · derivative.exercise_date: These options vest over three years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.

SEC source: 0002017800-25-000003 · form4-10162025_121025.xml · derivative · entry 1

Savchuk Nikolay · CIK 0002017800 · Director · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,435

Underlying: Common Stock · 22,435 shares

Expires 2035-10-12

F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0002018274-25-000003 · form4-10162025_121036.xml · derivative · entry 1

Redfield Robert · CIK 0002018274 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,406

Underlying: Common Stock · 32,406 shares

Expires 2035-10-12

F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0002018150-25-000003 · form4-10162025_121042.xml · derivative · entry 1

Pauza Charles David · CIK 0002018150 · Chief Science Officer Virology

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,406

Underlying: Common Stock · 32,406 shares

Expires 2035-10-12

F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001681955-25-000003 · form4-10162025_121051.xml · derivative · entry 1

Dukes Iain D. · CIK 0001681955 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,839

Underlying: Common Stock · 64,839 shares

Expires 2035-10-12

F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.

SEC source: 0001237419-25-000003 · form4-10162025_121028.xml · derivative · entry 1

CAUTREELS WERNER · CIK 0001237419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,530

Underlying: Common Stock · 11,530 shares

Expires 2035-10-12

F1 · derivative.exercise_date: The options vest 100% on the first anniversary of the grant date.